Posts about:
I recently had the pleasure of joining Real-World Wednesday, a conversation hosted weekly on Clubhouse covering various topics about real-world data. First off, I’d like to thank the hosts of the RWD-RWE Club, Matt Veatch and Aaron Kamauu, for the invitation and the engaging discussion.
Today, Digital Health New York (DHNY) released its Q1 Healthcare Innovation Report, of which we were honored to be a part.
At Holmusk, our vision is to provide fit-for-purpose real-world data that fuel research and innovation in behavioral health. With tons of data captured each day as patients move through healthcare systems—much of it in unstructured data fields—a lot goes on behind the scenes, as we ensure that this information is available and usable for research. Below, you’ll find a quick overview on the types of data that are included in the NeuroBlu Database—as well as the process data go through to ensure they are fit-for-purpose.
Earlier this month, the Substance Abuse and Mental Health Services Administration (SAMHSA) released its annual National Survey on Drug Use and Health (NSDUH), which examined substance use and mental health data from 2021. Although the survey has been administered since 1971, SAMHSA called this year’s “the most comprehensive report on substance use and mental health indicators” that the organization has released to date.
Over seven years ago, I founded Holmusk with the vision that advances in technology and data science could be harnessed to improve health care. Over the company’s lifespan, the vision has crystallized, and we decided to focus first on an area of dire need—behavioral health. We have made great advancements in this space, many of which would not have been realized without the creation and nurturing of fruitful and supportive partnerships.
What if we could better understand the effects of treatments on specific types of individuals, thereby allowing us to personalize drug treatments?
Today marks World Mental Health Day, a day of recognition organized and sponsored by the World Health Organization. All month, we will also honor ADHD Awareness Month by looking back at some of the most important ADHD research we have done this year.
This year at the American Society of Clinical Psychopharmacology’s annual conference, I had the privilege to organize and chair a panel discussion on challenges and opportunities in leveraging real-world evidence to inform the development of new treatments in behavioral health.
On Clinical Trials Day, we recognize an important part of the healthcare infrastructure: the studies that rigorously evaluate new treatments to determine which will be effective and safe for improving patient health. Through the conventional process of assessment, the treatments that succeed will go on to regulatory approval and will be marketed to patients and their providers.
